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Objective: We sought to document the feasibility, safety, and effectiveness of
performing mitral valve repair using a totally endoscopic approach.
Methods: Between February 1997 and October 1, 2001, 187 patients underwent
totally endoscopic mitral valve repair at our institution. The mean age was 60.7 
13.1 years, and 62% were male. Median preoperative functional class and degree of
mitral regurgitation were II and 4, respectively. Data collection included an insti-
tutional protocol assessing procedure-related pain, cosmesis, and functional recov-
ery. Statistical analysis included Kaplan-Meier and Cox regression methods. Mean
follow-up was 19  15.2 months and was 100% complete.
Results: Associated atrial procedures were performed in 9.1% (n  17) of the
patients. Two patients required intraoperative conversion to sternotomy. Thoraco-
scopic re-evaluation for suspected bleeding (n  19) was part of our aggressive
postoperative management. One patient required sternotomy for control of bleeding.
Hospital mortality included 1 (0.5%) patient and was not technology related. There
were 1 early and 6 late reoperations, 4 of which were due to endocarditis. No risk
factors for repair failure could be detected. Freedom from mitral valve reoperation
at 4 years was 93.3%  2.6%. The median degree of mitral regurgitation at
follow-up was 0. Ninety-three percent of the patients were highly satisfied with
either no or mild postoperative pain, and 98.4% believed they had an aesthetically
pleasing scar.
Conclusions: Totally endoscopic mitral valve repair can be done safely with excel-
lent results and a high degree of patient satisfaction. It is now our exclusive
approach for isolated atrioventricular valve disease.
In 1994, Heartport, Inc (currently part of Johnson & Johnson Corp, NewBrunswick, NJ), developed a technique for minimally invasive cardiacsurgery. The technique consists of an endo-cardiopulmonary bypass (En-doCPB) system, which is connected through the femoral artery and vein.The heart is arrested by using an endoaortic clamp and antegrade cardio-plegia administration, retrograde cardioplegia administration, or both. Ini-
tial dog studies demonstrated the feasibility and safety of the technique for both
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coronary artery bypass and mitral valve surgery.1-5 Clinical
experience confirmed this feasibility but also pointed out an
important learning curve and some technique-related major
adverse events.6 This attenuated the initial enthusiasm of
several centers.
In 1997, Heartport, Inc, obtained authorization from Eu-
ropean regulators for investigational clinical application of
its EndoCPB system. This meant the start of our clinical
program, and we have since used this technology for a
variety of indications. The majority of applications, how-
ever, were mitral valve repair procedures. This article ana-
lyzes our experience with mitral valve repair using the
EndoCPB system.
Methods
Between February 1997 and October 1, 2001, a total of 402
procedures were performed with the EndoCPB system (Johnson &
Johnson Corp) at our institution. Of these, 187 (46.5%) were mitral
valve repair procedures performed by a single surgeon (H.V.), and
this group constitutes the subjects of this study. This group of 187
patients represents 66.1% of all mitral valve repair procedures not
combined with coronary artery bypass grafting at the OLV Clinic
during the same time period. Initially, only simple repair proce-
dures and low-risk patients were considered for this technique. As
experience grew, more complex repair cases and higher-risk pa-
tients were also considered candidates for this technique. Cur-
rently, any mitral valve repair case, either isolated or combined
with tricuspid valve disease or atrial septal defect (ASD), is ap-
proached with this technique.
All patients were preoperatively fully informed about the tech-
nique and were able to choose a standard median sternotomy if that
was their preference.
Patients
The mean age of the patients was 60.7  13.1 years (range, 27-84
years), and 62% were male (n  116). Comorbidity was present in
113 (60.4%) patients and included atrial fibrillation in 40 (21.3%)
patients, arterial hypertension in 57 (30.5%) patients, chronic
obstructive pulmonary disease in 15 (8%) patients, peripheral
vascular disease in 2 (1.1%) patients, and insulin-dependent dia-
betes in 1 (0.5%) patient. Preoperative New York Heart Associa-
tion functional class was I in 33 (17.6%) patients, II in 72 (38.5%)
patients, III in 67 (35.8%) patients, and IV in 15 (8%) patients.
Left ventricular function was normal in 136 (72.7%) patients,
mildly impaired in 40 (21.4%) patients, moderately impaired in 8
(4.3%) patients, and severely impaired in 3 (1.6%) patients. The
mean preoperative left ventricular end-diastolic diameter was
58.6  7.14 mm (range, 32-79 mm). The mean preoperative left
ventricular end-diastolic volume index was 104.3  32 mL/m2
(range, 44-196 mL/m2). The left ventricle was preoperatively not
dilated in 54 patients.
Preoperative mitral valve disease is detailed in Table 1. The
patient with grade 2 regurgitation had an associated ASD. The
Carpentier classification was used to describe valve dysfunction.7
The median preoperative degree of mitral valve regurgitation was
4. All procedures were primary and elective interventions. In 2
patients the endoscopic mitral valve repair procedure was part of a
hybrid approach. Percutaneous transluminal coronary angioplasty
and stenting of the right coronary artery (n  1) and left anterior
descending artery (n  1) were both performed before the valve
procedure.
Postoperatively, chest tubes were routinely kept for 48 hours
(or longer if chest tube output remained sanguineous), regardless
of whether bleeding stopped earlier and fluid became serous.
Postoperative analgesia consisted of 10 mg of intravenous piritra-
mide (Dipidolor; Janssen-Cilag, Beerse, Belgium) and 10 mg of
intramuscular piritramide at the time sedation was stopped in the
intensive care unit. Once the patient was extubated, analgesics
were only given at the request of the patient. The patients were
anticoagulated with fenprocoumon (Hoffmann, Grenzach-Wyhlen,
Germany) for 3 months and were then switched to acetylsalicylic
acid unless they were in atrial fibrillation.
Surgical Technique
After achievement of general anesthesia, the patient is placed in
the supine position, with slight elevation of the right hemithorax.
All patients are ventilated with a double-lumen endotracheal tube.
A right radial arterial line is inserted. Next, a 14F or 17F DLP
cannula (Medtronic DLP, Grand Rapids, Mich) is placed percuta-
neously by the anesthesiologist through the internal jugular vein
into the superior vena cava. This is performed under transesoph-
ageal echocardiographic (TEE) guidance.
The right common femoral artery and vein are exposed by
using an oblique groin incision. A double pledget U stitch (4-0
polytetrafluoroethylene*) is placed at the anterior side of the
common femoral artery, and a double purse-string suture (4-0
polytetrafluoroethylene) is placed at the anterior side of the com-
mon femoral vein.
*Gore-Tex; registered trademark of W. L. Gore & Associates, Flagstaff,
Ariz.
TABLE 1. Preoperative mitral valve characteristics
(n  187)
Variable N %
Grade of regurgitation
2  1 0.5
3  58 31.0
4  128 68.4
Valve pathology
Degenerative 156 83.4
Fibroelastic deficiency 149 79.7
Barlow disease 7 3.7
Endocarditis 14 7.5
Sole annular dilatation 16 8.6
Congenital 1 0.5
Carpentiers functional classification
Type 1 17 9.1
Type 2 167 89.3
Posterior prolapse 136 72.7
Anterior prolapse 21 11.2
Prolapse of both leaflets 10 5.3
Type 3 3 1.6
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An anterolateral working port of 4 to 6 cm is made in the
midportion of the right inframammary groove, usually the fourth
intercostal space. A medium soft tissue retractor is inserted, but no
other rib retractor is used. A camera port is also made in the fourth
intercostal space but at the level of the anterior axillary line. Just
before the introduction of the camera, the right lung is deflated. At
the beginning of the procedure, a 0° camera is used, which is
switched to a 30° downward-looking camera once the left atrium
is opened and retracted. A venting port is made in the seventh
intercostal space at the level of the anterior axillary line; this port
also serves for carbon dioxide insufflation once the left atrium is
opened. A left atrial blade retractor is introduced into the right side
of the chest through the working port and connected to a 2-mm
shaft penetrating the chest wall in the fourth intercostal space, just
lateral to the right internal thoracic artery. When the right hemi-
diaphragm precludes a direct view on the left atrium, a pledget-
supported stitch is used to pull the dome down through the seventh
intercostal space (Figure 1).
The patient is heparinized, and the femoral vessels are cannu-
lated with a Seldinger technique. TEE is used to precisely intro-
duce and position the venous cannula (21F-25F) into the right
atrium at the junction with the inferior vena cava. Next, the arterial
cannula (21F-23F) is introduced, also by using the Seldinger
technique. The endoaortic balloon is positioned from the groin,
with TEE guidance, in the ascending aorta just above the sinotu-
bular junction. We always used the endoaortic balloon and have no
experience with the endo-direct transthoracic balloon cannula.
CPB with kinetic assisted venous drainage is instituted during TEE
monitoring. Once the pericardium is opened and the interatrial
groove is dissected, the endoaortic balloon is progressively inflated
with TEE guidance, carefully checking its position at the level of
the sinotubular junction. Once the balloon is approximately three
fourths inflated, the heart is arrested by means of rapid injection of
10 mL (0.25 mg/kg) of adenosine (Sanofi-Winthrop, Notre Dame
de Bondeville, France). Immediately thereafter, the balloon is
further inflated, and cold crystalloid antegrade cardioplegic solu-
tion is administered. While the endoaortic balloon is being inflated,
the right radial pressure should remain the same at all times
because any decrease in pressure might indicate a malpositioning
of the balloon (partially) occluding the brachiocephalic artery. The
volume of saline solution needed to inflate the balloon is depen-
dent of the size of the ascending aorta. The balloon pressure is kept
at approximately 350 mm Hg. During the remainder of the proce-
dure, an additional dose of 300 mL of cold crystalloid antegrade
cardioplegic solution is administered every 30 minutes. The aortic
root pressure is continuously measured and is usually between 0
and 30 mm Hg in the absence of cardioplegia administration. Its
value needs to be constant because a sudden increase of aortic root
pressure indicates a nonocclusive balloon. The left atrium is
opened, and the mitral valve is exposed with the left atrial blade.
The operative field is flooded with carbon dioxide and cleared of
blood by using the venting suction, which is positioned in the left
inferior pulmonary vein.
First, the annuloplasty stitches are placed, starting with the first
stitch at the anterolateral commissure. Next, 2 annuloplasty
stitches are placed on the anterior leaflet annulus just medial of the
anterolateral commissural stitch. Now all remaining annular
stitches are placed along the remaining annulus, starting at the
anterolateral commissural stitch, over the posterior annulus toward
the posteromedial commissure and then the medial portion of the
anterior leaflet annulus. All annular stitches are exteriorized
through the working port and fixed in suture guides. This maneu-
ver exposes the mitral valve completely.
Figure 1. Operative setup. All ports have been made. Note the central working port, the camera port, and the venting
port; the shaft that will hold the left atrial retractor has also been introduced in the chest (see text for details).
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Now the valve is analyzed according to the Carpentier guide-
lines.7 Posterior leaflet mitral valve repair is performed by using
the Carpentier techniques (Figure 2).7 Shafted instruments are
introduced in the chest and the left atrium through the working
port. The repair is performed with the exclusive aid of video
assistance. Knots are thrown extracorporeally and tightened with a
knot pusher. Anterior mitral leaflet prolapse is corrected with a
small triangular resection8 or with the creation of new polytetra-
fluoroethylene chords,9 depending on the extent of the prolapsing
area. Once the repair is completed (Figure 3), the left atrium is
closed, leaving the venting suction in place for deairing. In addi-
tion, suction is applied to the tip of the endoaortic balloon, and the
left lung is inflated before final closure of the left atrium. A bipolar
ventricular pacing wire (Bipolar pacing lead; Medtronic France,
Fourmiss, France) is placed before unclamping because it is oth-
erwise almost impossible to place. The aorta is unclamped, and
reperfusion is allowed. The valve repair is tested under TEE
guidance just before termination of CPB. Careful hemostasis is
performed after protamine hydrochloride (Roche, Fontenay-sous-
Bois, France) administration, and 2 drains are left in situ: 1
intrapericardial and 1 intrathoracic. Both drains are exteriorized
through an existing port. The pericardium is approximated, and the
working port and groin are closed intracutaneously.
Follow-up
All patients were seen at the outpatient clinic 2 months postoper-
atively, except patients who were operated on in October 2001.
They were then sent back to their referring cardiologists, who saw
their patients at 4 months and then usually yearly. Follow-up was
performed between August and November 2001. All patients and
their general practitioner, as well as the referring cardiologist, were
contacted to obtain clinical information and echocardiographic
follow-up data. The official guidelines were used to complete a
follow-up questionnaire.10 In addition to this information, patients
were asked about the amount of pain they experienced at the time
of the operation; they were also questioned about how fast they
had regained professional or expected activity postoperatively,
whether they were pleased with the aesthetic result of the opera-
tion, and whether they would prefer this technique again if they
were to choose between EndoCPB and standard median sternot-
omy. The mean patient follow-up was 19  15.2 months (range,
0.2-54.1 months) and was 100% complete. A total of 284 patient-
years was available for analysis. The New York Heart Association
functional class in 184 survivors at follow-up was class I in 149
patients, class II in 30 patients, and class III in 5 patients. At
follow-up, 156 patients were in normal sinus rhythm, 20 were in
atrial fibrillation, and 8 had pacemaker rhythm.
Assessment of Repair and Durability
All patients had immediate intraoperative postrepair TEE to assess
the repair. Repair durability was primarily assessed by the inci-
dence of reoperation. In addition, the latest echocardiographic
follow-up was analyzed to detect the presence of mitral regurgi-
tation. It was available in 178 of 180 patients who retained their
native valves at the time of follow-up. The mean echocardio-
graphic follow-up was 14.9  14.7 months (range, 0.1-53.8
months).
Data Analysis
The design of the study was retrospective, and data are expressed
as means  SD. Survival and event-free estimates were deter-
mined by means of Kaplan-Meier analysis11 and expressed as
proportions  SE. Analysis was performed with the Statistica
package, Release 5.1 (StatSoft, Tulsa, Okla).
Risk factors for outcome were evaluated by using the Cox
proportional hazard models. The first event was used as the out-
come. First analyses were performed by using only the risk factor
of interest in the Cox univariate model. Because none of the risk
factors showed a statistical significance of less or equal to 0.10, no
further multivariate Cox regression model could be applied. The
potential risk factors entered into the analysis of reoperation are
listed in the appendix.
Estimates of the linearized incidence rate with corresponding
SEs were obtained by dividing the number of events by the
corresponding patient-years of follow-up. The SE was calculated
as the square root of the incidence divided by the patient-years of
follow-up, assuming a Poisson distribution.
Figure 2. A flail P2 segment is resected endoscopically by using
the sliding technique.
Figure 3. Final repair result after a triangular resection in the A3
segment. The annuloplasty stitches are in place, but the ring is
not yet in place.
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Results
Immediate Technical Feasibility
The operative technique was successfully performed in all
but 2 patients. These 2 patients were operated on early in the
series and required intraoperative conversion to median
sternotomy. In one patient aortic dissection occurred intra-
operatively. This was repaired by using standard techniques.
The patient, however, had a stroke with residual hemiplegia.
The other conversion to median sternotomy was done be-
cause of the inability to reach adequate bypass flow through
the common femoral artery. This patient underwent stan-
dard mitral valve repair and recovered uneventfully.
The techniques used to perform mitral valve repair are
depicted in Table 2. Associated procedures were performed
in 17 patients: tricuspid annuloplasty in 6 (3.2%) patients,
atrial arrhythmia ablation in 6 (3.2%) patients, ASD in 3
(1.6%) patients, tricuspid annuloplasty and atrial arrhythmia
ablation in 1 (0.5%) patient, and a fibroelastoma of the
aortic valve in 1 (0.5%) patient. Mean aortic crossclamp and
CPB times were 91.4  23.7 minutes (range, 24-160 min-
utes) and 131.3  28.0 minutes (range, 74-215 minutes),
respectively.
Postoperative Course and Complications
One 71-year-old patient required a reintervention for failure
of mitral valve repair on postoperative day 1. This was done
through a median sternotomy, and valve replacement was
performed. The patient, however, had a low cardiac output
syndrome and died on postoperative day 5. This was the
only 30-day mortality in the series (0.5%).
Postoperative reintervention (through the same operative
approach) for suspected bleeding was performed in 19 pa-
tients. Reintervention was performed as soon as the chest
tube output exceeded 100 mL/h for 3 hours. Consequently,
an active bleeding source was found in only 9 instances. In
one patient, however, a median sternotomy had to be per-
formed to control the bleeding, which was located at the
pacemaker insertion. Other postoperative morbidity is de-
picted in Table 3. Of note is that there were no neurologic
events other than the one in the patient who underwent
aortic dissection, no wound infections (neither at the work-
ing port nor in the groin), and no deep venous thromboses
after femoral vein cannulation.
The mean postoperative chest tube output was 1223 
1115 mL (median, 750 mL); 61.5% of the patients had a
total chest tube output of less than 1000 mL. Bleeding was
secondary to abnormal clothing factors in 19.3% of the
patients. The mean transfusion rate was 3.7  4.5 units per
patient (range, 0-25 units; median, 2 units), and 25.7% of
the patients did not receive a transfusion. The mean inten-
sive care unit stay was 35.4  25.4 hours (median, 23
hours), with 68.5% being discharged within 24 hours and an
additional 18.2% within 48 hours. The mean hospital stay
was 8.4  4.8 days (median, 7 days), with 71.1% of the
patients discharged within 8 days.
Durability of the Repair
Reoperation. As stated earlier, there was one early fail-
ure of repair requiring reoperation on postoperative day 1.
In addition, there were 6 late reoperations at a mean of
13.9  7.1 months after the initial procedure. Causes of
reoperation were endocarditis in 4 patients and recurrent
mitral valve regurgitation in 2 patients (in one patient reop-
TABLE 2. Mitral valve repair techniques used in the present
series (n  187)
Valve repair technique N %
Posterior leaflet quadrangular resection 134 71.7
Posterior leaflet sliding plasty 68 36.4
Anterior leaflet triangular resection 9 4.8
Anterior leaflet PTFE neochordae 17 9.1
Resection of both leaflets 4 2.1
PTFE neochordae of both leaflets 3 1.6
Chordal shortening 3 1.6
Chordal transfer 1 0.5
Calcium debridement 6 3.2
Commissuroplasty
Anterolateral 1 0.5
Posteromedial 1 0.5
Annuloplasty
Type
Carpentier-Edwards Physio ring 183 97.9
Carpentier-Edwards Classic ring 4 2.1
Size
28 22 11.8
30 32 17.1
32 39 20.9
34 61 32.6
36 29 15.5
38 4 2.1
PTFE, Polytetrafluoroethylene.
TABLE 3. Perioperative and postoperative complications
(other than death and reintervention, n  187)
Type of complication N %
Pneumonia 2 1.1
Prolonged ventilation (72 h) 10 5.4
Subcutaneous emphysema 7 3.7
New-onset atrial fibrillation 30 16
Pacemaker implantation 4 2.1
Myocardial infarction 1 0.5
Renal insufficiency 3 1.6
Neurologic event 1 0.5
Peripheral ischemic event 0 0
Deep venous thrombosis 0 0
Wound infection 0 0
Groin lymphocoele 12 6.4
Postoperative drainage of right
pleural effusion
4 2.1
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eration was necessitated by progressive left ventricular di-
latation after myocardial infarction). All these patients un-
derwent valve replacement with median sternotomy used as
the surgical approach. The patient undergoing early reop-
eration died on postoperative day 5. No other patient died at
reoperation. The freedom from mitral valve reoperation was
99.5%  0.5% at 30 days, 97.1%  1.4% at 1 year, and
93.3%  2.6% at 4 years (Figure 4). The linearized inci-
dence rate was 2.5%  0.06% per patient-year. No risk
factors for repair failure could be detected univariately.
Consequently, a multivariate risk factor analysis could not
be performed.
Echocardiographic follow-up. Late echocardiographic
follow-up was available in 178 (98.9%) of the 180 patients
with retained native mitral valves at the time of follow-up
(in the 2 late-death patients we included the last TTE before
death). Mean echocardiographic follow-up was 14.9 14.7
months. The median degree of mitral valve regurgitation
was 0. A total of 116 (64.4%) patients had no residual mitral
valve regurgitation, 48 (26.7%) patients had 1 regurgita-
tion, and 12 (6.7%) patients had 2 regurgitation. Two
patients had 3 mitral valve regurgitation at follow-up.
They are currently asymptomatic and closely monitored.
Other Follow-up Events
One early death and 2 late deaths occurred. One patient died
suddenly on postoperative day 49, and another patient died
on postoperative day 497 after a cholecystectomy. Survival
was 99.5%  0.5%, 98.9%  0.8%, and 97.8%  1.3% at
30 days, 1 year, and 4 years postoperatively, respectively
(Figure 5). The linearized incidence rate for death was 1.0%
 0.03% per patient-year.
As stated earlier, one patient with aortic dissection had a
stroke with permanent residual hemiplegia. During follow-
up, another 16 anticoagulation-related complications oc-
curred. Three of these were second events. None of these
events resulted in permanent neurologic damage. The lin-
earized incidence of anticoagulation-related complications
was 5.1%  0.08% per patient-year. Freedom from the first
anticoagulation-related complication was 98.9%  0.8%,
93.8%  2.0%, and 84.2%  4.8% at 30 days, 1 year, and
4 years postoperatively (Figure 6).
Four patients had endocarditis during follow-up at a
mean of 13.2  7.4 months postoperatively. These patients
all had recurrent mitral valve regurgitation and were reop-
erated on by using a median sternotomy. All of them un-
derwent valve replacement. Freedom from endocarditis was
100% 0%, 98.4% 1.1%, and 95.9% 2.1% at 30 days,
1 year, and 4 years postoperatively. The linearized inci-
dence was 1.4%  0.04% per patient-year.
Patient Satisfaction
Procedure-related pain. Of all patients, 93.5% stated
they experienced minimal to almost no procedure-related
pain. None of the remainder mentioned excessive proce-
dure-related pain.
Postoperative recovery. Of patients, 33.7% were back at
work or at routine activity within 4 weeks postoperatively.
Another 26.6% were back at this activity level within 8
weeks postoperatively. Patient age did not influence post-
operative recovery (P  .14).
Cosmesis. An overwhelming 98.4% of the patients were
extremely pleased with the cosmetic result of the procedure.
In 41.9% of the patients, the scar was hardly visible any
more.
Choose again? In 92.4% of the patients, the patient
would choose the same procedure if he or she was to face
the same operation again.
Figure 4. Freedom from mitral valve reoperation.
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Discussion
“Surgery is exposure” is a statement that many of us heard
constantly during our surgical training. In minimally inva-
sive cardiac surgery, exposure is still of paramount impor-
tance but is now created intrathoracically and visualized
through video assistance. This requires a definite learning
curve and a different surgical attitude from the surgeon and
his or her assistant. In fact, both need to adopt the 4 major
changes characterizing this technique: the use of the En-
doCPB system and endo-clamp; the use of shafted instru-
ments; video assistance as the surgeon’s eye; and TEE for
supervision of the entire procedure. Indeed, every step of
the procedure, from catheter insertion to the final surgical
result, is controlled by TEE. Previously, our group and
others have stressed the usefulness and necessity of preop-
erative TEE guidance by an experienced person.12-16
The present series, which includes our initial experience
and thus our learning curve, demonstrates that the procedure
can be safely performed with good results. The 30-day
mortality in this series was 0.5%, a figure comparing favor-
ably with those of some of the major classic mitral valve
repair studies17-19 and with that of another initial experience
report.6 Our learning period did, however, include one aor-
tic dissection. This 0.5% occurrence is lower than the initial
experience of Mohr and colleagues6 but higher compared
with that of other groups.20-22 To avoid this complication,
Figure 5. Postoperative survival.
Figure 6. Freedom from anticoagulation-related complications.
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we suggest that our cardiologists inject the right iliac artery
at the time of heart catheterization to identify iliac artery
stenosis.
The smallest femoral artery cannula available is a 21F
cannula. The femoral artery therefore needs to be able to fit
this cannula and provide adequate flow, a condition that was
not fulfilled in one of our patients. To date, we have been
unable to correlate inadequate femoral size to another pa-
rameter, such as body surface area. However, in addition to
severe peripheral vascular disease, a small femoral artery is
clearly a contraindication for the use of the EndoCPB sys-
tem. Other contraindications include excavated pectus (this
condition substantially reduces the anteroposterior diameter
of the chest and displaces the heart to the left, both of which
preclude direct access to the left atrium), aortic regurgitation
of greater than grade 1 (precluding the use of antegrade
cardioplegia administration), severely atherosclerotic as-
cending or descending aorta (which dramatically increases
the stroke risk with endovascular manipulation), and dense
adhesions in the right hemithorax.
Although others demonstrated a lower blood transfusion
ratio in minimally invasive procedures versus standard ster-
notomy,23-25 our high reintervention rate, median chest tube
output, and transfusion rate do not seem to be so favorable.
Introducing this technique in 1997, we were extremely
cautious and anticipated a markedly reduced blood loss
because of reduced tissue trauma. Therefore, we aggres-
sively took patients back by using the same operative ap-
proach but found an active bleeding source in only half of
the patients. In all other cases, the right hemithorax was
rinsed, and cloths were evacuated. Also, all chest tubes
remained in place for 48 hours, even when bleeding had
stopped after a few hours postoperatively and chest tube
output was just serous fluid. This of course also negatively
influenced the total amount of chest tube drainage. On the
other hand, we do have a very liberal use of blood products,
which is reflected in the low transfusion-free proportion of
the study population. In addition, quite a high proportion
(19.3%) required correction of coagulation parameters, pre-
sumably related to the relatively long pump run. Neverthe-
less, we changed a few things during the study period to
reduce excessive bleeding: the pericardial fat is now re-
sected only if it avoids direct approach to the left atrium,
and the pacemaker wire is now always placed on the inferior
side of the left ventricle, where the thicker muscle avoids a
muscle tear caused by the pacemaker wire.
One might argue that the presented surgical technique is
not a totally endoscopic procedure because a working port is
made. This 4- to 6-cm incision could be used by the surgeon
to directly look inside the chest. This working port, how-
ever, is only made to permit instrument handling and intro-
duction of an annuloplasty ring. We only use the soft tissue
retractor and never spread the ribs, as is done by some other
groups.25,26 The soft tissue retractor is used to minimize
postoperative pain but, at the same time, forces the surgeon
to look at the screen, thereby totally relying on video
assistance for the entire procedure. We therefore consider
the procedure totally endoscopic.
The freedom from mitral valve reoperation in the present
series was 93.3%  2.5% at 4 years (Figure 4). This is
lower than previously reported in other series of degenera-
tive valve disease, where the same percentage of freedom
from mitral valve reoperation is reached at approximately
10 years.17,18 However, only 3 of the 7 reoperations were
due to failed mitral valve repair. The 4 others were due to
endocarditis. In fact, the linearized incidence rate for endo-
carditis was 1.4% 0.04%, which is rather high. We do not
know why the incidence of endocarditis in the present series
was so high, but it definitely influenced our reoperation rate
negatively.
Patient satisfaction in the present series was very high.
More than 98% of the patients were extremely pleased with
the cosmetic result of the procedure. Forty-two percent even
stated they could hardly see the scar any more. Also, pro-
cedure-related pain was very favorably assessed in greater
than 93% of the patient cohort, and no patients reported
excessive postoperative pain. Other authors also reported
favorable postprocedural pain perceptions, both with the
current technique27 and after other minimally invasive mi-
tral valve surgical techniques.26,28 In addition, almost 34%
of the patients were fully recovered within 4 weeks. Faster
recovery of patients undergoing minimally invasive opera-
tions versus that of patients undergoing standard sternotomy
was demonstrated by Glower and coworkers.24 In the
present series an additional 27% of the patients fully recov-
ered within 8 weeks postoperatively. All these factors un-
doubtedly contributed to the high patient satisfaction rate.
Almost 93% of the patients would prefer the same operative
technique if they were to start all over again.
Finally, one might consider endoscopic mitral valve re-
pair by using video assistance, a transition phase toward
robotic mitral valve surgery.29 Although mitral valve repair
without the use of a working port has recently been report-
ed,30 we do not feel the need for such a device in mitral
valve surgery. Using the current technique, we are able to
repair complex cases and have never felt the absence of
voice-controlled devices or extra robot-controlled surgical
tools to be a shortcoming.
In conclusion, the present series demonstrates the feasi-
bility, reproducibility, and medium-term durability of the
EndoCPB technique for mitral valve repair. The technique
provides ample patient satisfaction and is currently our
technique of choice for isolated atrioventricular valve dis-
ease.
The major limitation of this study is its retrospective
nature. Although the general cardiac surgery data are pro-
Surgery for Acquired Cardiovascular Disease Casselman et al
280 The Journal of Thoracic and Cardiovascular Surgery ● February 2003
A
CD
spectively collected in our database, the more specific pro-
cedure-related data were retrospectively collected. How-
ever, we hardly encountered missing data, presumably
because of our high interest in this procedure.
The retrospective nature of the study might have posi-
tively influenced the procedure-related pain sensation be-
cause patients were asked about procedure-related pain at
the time of follow-up. Because the majority of the patients
were very satisfied with the procedure and the cosmetic
result, periprocedural pain sensation might have been
judged more positively than would have been the case if
patients were interviewed immediately postoperatively.
This is not the case for the postoperative recovery period
because this was checked with specific dates or events for
every patient.
A prospective randomized trial would be the best ap-
proach to truly evaluate the (positive) effect of this opera-
tive technique versus a standard median sternotomy ap-
proach. However, this is impossible to realize in our center
because patients are specifically referred for the endoscopic
technique and therefore unwilling to participate in a ran-
domized trial.
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Appendix
Potential Risk Factors (Variables)
Demography
Age at repair
Sex
New York Heart Association functional class
Mitral valve disease
Prolapse of anterior leaflet
Prolapse of posterior leaflet
Chordal rupture of anterior leaflet
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Chordal rupture of posterior leaflet
Annular dilatation
Barlow disease
Left atrial diameter
Left ventricular function-dimension
Grade of left ventricular dysfunction
History of myocardial infarction
Left ventricular dilatation
Comorbidity
Preoperative atrial fibrillation
Insulin-dependant diabetes mellitus
Arterial hypertension
Chronic obstructive pulmonary disease
Peripheral vascular disease
Renal failure
Repair
Leaflet resection
Sliding leaflet repair
Chordal shortening
Use of neochordae
Discussion
Dr Delos M. Cosgrove (Cleveland, Ohio). Drs Vanermen and
Casselman are to be congratulated on excellent results that they
have reported using a small right anterior thoracotomy and endo-
scopic visualization. Their report demonstrates a very low opera-
tive mortality rate and advantages in terms of cosmesis and min-
imal amounts of pain. However, these have not been achieved
without a very significant learning curve, prolongation of aortic
crossclamp and cardiopulmonary times, and a 10% incidence of
reintervention for bleeding. It is of interest that only two thirds of
mitral valve repairs during this period were undertaken in this
manner, thus suggesting a limitation in the applicability of this
method.
We have experience with this approach and compared it with a
limited anterior sternotomy. In a pilot study we were unable to
demonstrate clinical advantages when compared with a limited
sternotomy. We did, however, note an increased equipment ex-
pense of $5000 and significantly longer operating room time.
I have a few questions for the authors. Is this approach appli-
cable to all diseases of the mitral valve? If so, what percentage of
all your primary isolated mitral valve operations are performed
with these techniques?
Second, what are the cost implications considering the in-
creased equipment costs and presumed longer operating room
times?
Finally, would you recommend that this technique be adopted
universally as a standard practice for mitral valve surgery?
Dr Vanermen: Thank you very much, Dr Cosgrove, for your
questions. Your points are very well taken because I think that is
what it is all about when it comes to implementation of new
technology. There is a lot of new technology coming up in the 21st
century. We should be able to recognize which might be useful and
which might not, and that is the first step.
The second step is procedural development. That is the most
difficult part, and I can tell you that in this case it was blood, sweat,
and tears. Therefore, in the beginning it would have been unwise
to adapt this technique to every abnormality of the mitral valve.
Not everyone in our team adopted the technique, and we started
with the easy cases. At this very moment, we would treat all
isolated mitral valve abnormalities this way.
The learning curve was difficult, and I am not predictive
enough to say when all mitral valve surgery will be endoscopic. I
hope that will be the case one day for the patients. But the learning
curve is difficult, and people should not commit the same mistakes
and encounter the same obstacles we encountered in the beginning
of our experience. At a certain moment beyond the learning curve,
this should become a routine operation, and then the teaching
commences. We hope that it will be generally used one day.
As far as cost is concerned, there is no evidence thus far that the
undoubtedly higher in-hospital cost is compensated for by the
absence of procedure-related pain, the absence of scar-related
problems, and the faster rehabilitation.
Dr F. W. Mohr (Leipzig, Germany). Dr Vanermen, I would
like to congratulate you for your pioneering work. As you well
know, we do have our own experience with that procedure in about
600 patients, and we have eliminated the cost concerns from Toby
Cosgrove by eliminating the balloon after 200 patients and just
using a straightforward crossclamp, transthoracic clamp, which
had a significant effect also on neurologic problems.
I just have one question for you, which I think you failed to
mention, concerning the advantage of such procedures in redo
operations, patients who had previous coronary bypass surgery,
and patients who had previous aortic valve replacements. Could
you comment on this aspect too?
Dr Vanermen: Your point is very well taken, Dr Mohr. It is
true, and this is an extremely valuable technique in all those cases
when patients actually had sternotomy or redo sternotomy already
and had thoracic grafts in front of their ascending aorta. If you had
to go to the mitral valve then, it becomes easy if you apply this
endoscopic technique and if you go through a very small right
lateral thoracotomy. In those patients the balloon obviously is
extremely useful, too. And I can imagine that sometimes you can
clamp the aorta with a transthoracic clamp. Through the small
incision I have made, it is impossible to actually control the
bleeding site on the ascending aorta if something occurs when you
withdraw your aortic cannula or when you withdraw your car-
dioplegic cannula in the ascending aorta.
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